Florida Avenue, Suite H., Lakeland, Florida 33813 Fellowship Alcoholics Anonymous (AA) Hours Monday 9:00 am - 5:00 pm Brevard Intergroup 720 E
: BPC-157 + TB-500 BPC-157 TB-500 GHK-Cu 6 Peptide Lab &
Protocol 2: significant weight loss (20-25% body weight) Goal: Substantial weight reduction for health improvement Tirzepatide approach: Full escalation to 10-15 mg Expect to reach target dose by week 17-21 Weight loss at 15 mg: approximately 22.5% at 72 weeks Plateau typically occurs around weeks 60-72 Retatrutide approach: Full escalation to 8-12 mg Expect to reach target dose by week 13-17 Weight loss at 12 mg: 24.2% at 48 weeks, 28.7% at 68 weeks No plateau observed in trial data at 48 or 68 weeks For significant weight loss goals, retatrutide reaches 20%+ body weight reduction faster and ultimately achieves a higher ceiling
The gradient was programmed as follows: 02 min 35% B, 28 min from 35 to 80% B, 822 min from 80 to 99% B, 2236 min 99% B, and 36.140 min from 99 to 35% B
Suggested Use Consume one capsule daily
With Zepbound, 89.3% received at least one dose of the 15 mg dose and with Wegovy 92.8% received at least one dose of the 2.4 mg dose